Advertisements

Betamaks

Quick links to important sections

Betamaks

Selected form

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Betamaks

Property Description
Active ingredient Sulpiride (Sulpiridum)
Pharmacological class Psycholeptic, Antipsychotic Agent
Origin Synthetic Compound (Substituted Benzamide Derivative)
Forms Tablets, Capsules, Oral Solution, Intramuscular Injection Solution
Common Use Stabilizing mood and normalizing thought processes

What Type of Medicine is Betamaks (Sulpiride)?

Betamaks is a synthetic, prescription-only medicine containing the active ingredient Sulpiride, which is classified as a psycholeptic and an antipsychotic agent. The compound Sulpiride itself is a substituted benzamide derivative, a chemical group known for its specific effects on the central nervous system.

This medication is grouped under the Anatomical Therapeutic Chemical (ATC) code N05AL01, placing it within the family of Benzamide antipsychotics. Its function is primarily that of a selective dopamine receptor antagonist (D2 and D3), a mechanism involved in regulating thought and emotional processes.

Composition, Forms, and General Therapeutic Purpose

Betamaks is consistently manufactured as a single-ingredient product, with Sulpiride as the sole active compound. The medication is available in multiple dosage forms for systemic administration, which aids therapeutic flexibility. These forms include common oral preparations such as tablets, capsules, and solution, alongside a specialized parenteral form designed for intramuscular injection solution.

The core therapeutic purpose of Betamaks stems from its dose-dependent effects and a bimodal activity profile. This highly selective property means the medicine is capable of either modulating neurotransmitter activity for mood stabilization or providing suppression of excess dopamine signaling for behavioral regulation. By influencing these messengers, the drug aims to restore the neurochemical equilibrium necessary for cognitive clarity and sustained emotional control.

Advertisements

What side effects are possible with Betamaks?

Possible Side Effects and Safety Information

The safety profile of Betamaks (Sulpiride) is officially documented by government health authorities and categorizes adverse reactions primarily by frequency and the body system affected.

Commonly Documented Adverse Reactions

The most commonly reported adverse reactions are often related to the endocrine and nervous systems. These include Hyperprolactinaemia (increased prolactin levels), which may lead to associated symptoms, as well as Extrapyramidal disorders (such as parkinsonism, akathisia, and tremor) and general effects like sedation and insomnia. Other common effects include constipation and elevated liver enzymes.

Classification Examples of Reactions
Common Hyperprolactinaemia, Sedation, Extrapyramidal Disorders
Rare Convulsions/Seizures
Frequency Not Known Neuroleptic Malignant Syndrome (NMS), Torsades de Pointes, Agranulocytosis

Serious Adverse Reactions

Regulatory documents highlight rare but medically significant risks. These include the potential for Neuroleptic Malignant Syndrome (NMS), a severe general disorder. The medicine is also associated with QTc interval prolongation, which carries a documented risk of a serious cardiac event called Torsades de Pointes. Severe blood disorders, such as Agranulocytosis, have also been reported.

Safety Considerations for Specific Populations

Safety notes for specific groups are included in regulatory labeling. Older adults are documented as being more susceptible to effects such as sedation and postural hypotension. Renal impairment requires consideration, as the dose must be adjusted due to the medicine's elimination pathway. Furthermore, Tardive Dyskinesia is a specific neurological effect associated with prolonged treatment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents emphasize that taking doses of this substance much higher than recommended, whether accidentally or intentionally, carries a high risk of life-threatening complications. These severe complications define the official overdose profile and require immediate emergency medical attention.

Documented Overdose Risks

Overdose is primarily associated with two major physiological domains:

Risk Domain Potential Manifestations
Severe Cardiac Events Abnormal heart rhythms (including QT interval prolongation and Torsades de Pointes) and cardiac arrest.
Central Nervous System (CNS) Depression Extreme drowsiness, miosis (pinpoint pupils), unresponsiveness, and coma.

These severe adverse events, particularly the cardiac and respiratory complications, may result in death. Because of this severity, regulatory warnings mandate specific actions for individuals experiencing or witnessing an overdose.

Emergency Action is Required

Immediate emergency medical attention must be sought if any signs of a potential overdose occur, which includes fainting, unresponsiveness, or a rapid or irregular heartbeat. In the event of an overdose in a clinical setting, treatment is focused on providing supportive care. The medication naloxone is specifically indicated for managing the CNS symptoms of depression and coma. Due to the potentially prolonged action of the substance, repeated doses of naloxone may be necessary to maintain a patient's breathing and consciousness.

Advertisements

Therapeutic Uses of Betamaks

What Betamaks treats: main uses and benefits

Betamaks is commonly used across multiple symptom-driven clinical domains to provide supportive relief and is relevant for easing acute or chronic manifestations of distress, primarily focusing on psychiatric and neurobehavioral conditions. The medication is relevant when supportive symptom management is appropriate to help address complex psychiatric symptoms in conditions where functional stability becomes affected.

This medication is generally used to help address a range of conditions, including schizophrenia, major depressive episodes, and severe disruptive behavioral symptoms, as well as specific chronic dizziness or vertigo syndromes.

“A key benefit is in helping to ease the impact of symptoms on routine activities and helping patients maintain functional stability during difficult episodes.”


Symptomatic Relief and Therapeutic Focus

The medication is relevant in conditions characterized by periods of heightened symptoms where the need is to address severe positive symptoms (like hallucinations and delusions) or chronic negative symptoms (such as profound apathy and lack of motivation). It is often used during phases when symptoms become more noticeable and interfere with daily functioning. By providing supportive relief, the treatment contributes to easing the overall symptom load and helps improve day-to-day comfort and engagement. The therapeutic approach may assist with reducing the impact of distressing thoughts and supports in managing challenging neurobehavioral patterns.


Quick Fact: Relief for Psychotic and Behavioral Symptoms The medication assists with managing symptom clusters that may become intense or disruptive, supporting patients during episodes of heightened discomfort related to thought, mood, and behavior.

Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Restriction Rules

Betamaks (Sulpiride) is approved for use in adults, with specific restrictions and prohibitions defined by regulatory authorities. Use is conditional or not recommended for several populations, based on official safety and efficacy data.

Classification Population or Condition
Contraindicated (Prohibited Use) Patients with phaeochromocytoma, acute porphyria, or prolactin-dependent tumours (e.g., breast cancer, pituitary prolactinoma). Individuals with known hypersensitivity to sulpiride or taking Levodopa/Ropinirole.
Not Recommended Children under 14 years of age (insufficient clinical experience). Pregnant women, particularly during the first 16 weeks, and breastfeeding mothers (drug is excreted into breast milk).
Use with Caution Elderly patients (risk of sedation, hypotension, and increased mortality risk in those with dementia-related psychosis). Patients with renal impairment (requires dose reduction). Individuals with a history of epilepsy, heart problems, or diabetes mellitus (requires close monitoring).

These official rules strictly govern the use of the medicine, defining mandatory exclusions and conditions for treatment.

Advertisements

What should I know about interactions with other medicines?

The interaction profile for Betamaks is defined by several regulatory constraints concerning pharmacodynamic and pharmacokinetic effects. Formal regulatory documents classify co-administration with Levodopa and other dopamine agonists (e.g., Ropinirole) as strictly contraindicated, due to the reciprocal antagonism of their effects.

Significant pharmacodynamic risks are documented for combinations that affect the central nervous system and cardiac repolarisation. Concomitant use with Alcohol (Ethanol) and other CNS depressants (e.g., narcotics, benzodiazepines) is discouraged as it enhances sedative effects. Furthermore, combining Betamaks with QT-prolonging agents (e.g., specific antiarrhythmics) or Hypokalaemia-inducing medicines (e.g., certain diuretics) increases the risk of serious ventricular arrhythmias, such as Torsade de Pointes.

A necessary pharmacokinetic rule addresses systemic exposure: agents like Antacids and Sucralfate reduce the absorption of Sulpiride. To mitigate this effect, official labels require Betamaks to be administered at least two hours before these non-absorbable substances. While Sulpiride is officially documented as having no clinically significant interaction risk on co-administered drugs via the CYP450 enzyme system, caution is noted in the elderly population regarding the use of antihypertensive agents due to the enhanced possibility of postural hypotension. These requirements govern safe co-administration based on official risk assessment.

Advertisements

Mechanism of Action

Betamaks acts as a selective antagonist at the beta1-adrenergic receptor (AR), the predominant beta-AR subtype within myocardial tissue. This interaction blocks the binding of endogenous catecholamine agonists, such as norepinephrine and epinephrine, thereby preventing the initiation of the beta1-AR signaling cascade.

At the molecular level, antagonism of the Gs protein-coupled beta1-AR prevents the activation of adenylyl cyclase. This results in the inhibition of the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The subsequent intracellular decrease in cAMP concentration limits the activation of protein kinase A (PKA). Decreased PKA activity leads to reduced phosphorylation of key regulatory proteins, including L-type calcium channels and phospholamban.

System-level physiological consequences involve the modulation of cardiac function. Specifically, the reduction in calcium flux into cardiomyocytes results in a diminished rate and force of myocardial contraction. The antagonism also decreases the rate of sinus node discharge and prolongs the refractory period within the atrioventricular node, resulting in a systemic reduction of heart rate and myocardial oxygen demand.

Advertisements

Dosage and Administration Information

Betamaks is administered primarily through the oral route, available in multiple forms including tablets, capsules, and solution. A specialized intramuscular (IM) injection form is also approved, generally intended for short-term use during initial treatment phases before transitioning to the standard oral regimen.

The standard adult daily dose is administered in divided doses, typically twice daily. There is a wide dosage range, from 400 mg to a maximum of 2400 mg daily, where the final dose is selected according to a titration logic based on the specific clinical pattern being managed. For instance, regimens may range from 400 mg per day up to 1200 mg twice daily.

For proper administration, oral tablets must be swallowed whole with water and must not be crushed. A required instruction is the need for temporal separation from certain concomitant medications: Betamaks must be taken at least two hours before any antacids or sucralfate to prevent reduced absorption of the active substance. Dose reduction is mandatory for patients with impaired renal function and is applied to older adults with signs of kidney compromise. The medicine is not recommended for children under 14 years due to insufficient clinical experience.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Betamaks

Evidence for Schizophrenia and Mood Stabilization

The evaluation of Betamaks has focused significantly on its use in conditions associated with acute or disruptive episodes, such as schizophrenia and major depressive episodes. The foundation of this evidence includes Randomized Controlled Trials (RCTs) that involved adult patients, where the medicine was evaluated against both an inactive substance (placebo) and other established medications. The research explored how symptoms evolved over time and the patterns of change that were observed in these research settings.

Researchers examined outcomes related to change in mental state, utilizing standardized rating scales to measure symptoms such as delusions and hallucinations (positive symptoms). Trials also explored outcomes reflecting daily functioning and overall quality of life. Systematic reviews suggest that while the medicine was studied for a wide range of symptom patterns, the evidence base for a consistent pattern of superior symptom change compared to placebo in short-term RCTs has been described as limited.

Evidence for Chronic Dizziness and Vertigo Syndromes

The medicine was also studied for conditions involving periods of heightened symptoms such as specific forms of chronic dizziness and vertigo. This evidence was observed in randomized prospective studies where patients were evaluated against those receiving conventional vestibular suppressants. The research examined outcomes related to functional imbalance and patterns of change in vestibular dysfunction. Findings describe patterns observed in the studies that were associated with different functional changes over the measured period when evaluated against conventional treatment groups in those specific study populations.

What Remains Under Research and Key Limitations

The core efficacy evidence comes from controlled trials where follow-up durations were often limited (e.g., 6 to 12 weeks). Therefore, long-term outcomes are not fully established by the controlled research. Many foundational RCTs had sample sizes that were modest, and the findings were mixed regarding the medicine’s specific effect on negative symptoms in schizophrenia research, meaning certainty remains low in this specific domain.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Betamaks (FAQ)


Q: What is Betamaks actually used for?

According to regulatory documents, Betamaks is primarily used for managing symptoms associated with acute and chronic schizophrenia. Regulatory information also describes its use for certain forms of chronic dizziness and vertigo syndromes. In some contexts, low doses have been examined for the management of depressive disorders.


Q: Is Betamaks the same as other medicines for the same condition?

Betamaks contains the active ingredient Sulpiride, which belongs to a distinct chemical family known as Benzamide antipsychotics. Official classifications indicate that it is structurally separate from other older types of antipsychotic medications, such as phenothiazines.


Q: How quickly does Betamaks usually start working?

Official product information suggests that the full therapeutic benefits of Betamaks are generally not experienced immediately upon starting treatment. It may take several days or a few weeks of regular use for the intended effects of the medicine to be fully established.


Q: What happens if I miss a dose of Betamaks?

Regulatory guidance on administration suggests taking a forgotten dose only if there is still a significant amount of time before the next scheduled dose. If the next dose time is close, the missed dose should be skipped to maintain the regular schedule. Regulatory guidance instructs that a double dose should not be taken to compensate for the missed dose.


Q: Can Betamaks cause fatigue or tiredness?

Official product information confirms that feelings of drowsiness or feeling tired are among the documented adverse reactions. This effect is listed as common in the official safety profile of the medicine.


Q: Are there any food or drinks that interact with Betamaks?

Official guidance states that Betamaks may be taken with or without food. However, official prescribing information requires the medicine to be taken at least two hours before antacids or sucralfate to prevent reduced absorption of the active substance.


Q: Will Betamaks affect my birth control pills?

A common adverse reaction to Betamaks is hyperprolactinaemia (increased prolactin levels), which may disrupt the regular menstrual cycle. Official patient information directs that patients inform their health professional if they are using hormonal contraceptives.


Q: Does Betamaks interact with common over-the-counter pain relievers?

Regulatory documents indicate that pain relief medicines, including those found in common over-the-counter cold and flu products, can potentially interact with Betamaks. Official documents indicate the need to inform the doctor or pharmacist about any pain relievers being taken.


Q: How long can I expect to take Betamaks?

The duration of use is determined based on the condition being treated and the patient’s response. For some chronic indications, treatment is described in clinical summaries as generally long-term, requiring periodic review and monitoring by a health professional.


Q: What happens when I stop taking Betamaks?

Stopping the use of Betamaks suddenly is generally not recommended, as it carries a risk of the underlying condition worsening or causing the transient return of symptoms. Regulatory guidance requires that any decision regarding the discontinuation of treatment be made under the supervision of a health professional.


Q: Are there different versions or strengths of Betamaks?

Official labeling confirms Betamaks is available in several forms, including oral tablets in various strengths, such as 50 mg, 100 mg, and 200 mg. The medication is also manufactured as an oral solution and a solution for intramuscular injection in defined strengths.


Q: Does Betamaks show up on a standard drug test?

The active ingredient, Sulpiride, can be detected in biological samples using specialized laboratory methods. While this testing is sometimes used clinically to assess adherence, it is not established in available regulatory summaries if the drug is routinely included on all standard drug screening panels.


Q: What is the difference between Betamaks and a generic version?

The active ingredient in Betamaks is Sulpiride. Regulatory definitions state that a generic version contains the identical active ingredient and must meet the same strict quality and performance standards as the original brand-name product.


Q: Does Betamaks cause weight gain or weight loss?

Weight gain is a documented adverse reaction that is associated with the use of this medicine.


Q: Is it normal to feel nauseous when beginning Betamaks?

Gastrointestinal issues, including nausea, are documented as common adverse reactions. These symptoms are often reported, particularly when treatment is first initiated or when the dosage is increased.


Q: What are the long-term effects of taking Betamaks?

Long-term use is associated with potential risks such as Tardive Dyskinesia, which is a neurological effect. Regulatory documents indicate that long-term use warrants close monitoring for metabolic changes, including blood sugar levels and lipid imbalances.


Q: Is Betamaks addictive?

Betamaks is not classified by regulatory bodies as an addictive substance. However, due to the risk of symptom return, official guidance indicates that treatment should be stopped gradually under professional supervision.


Q: Can I take other prescription medications with Betamaks?

Official regulatory documents indicate that patients must inform their health professional about all other prescription and non-prescription medicines being taken. This is necessary because Betamaks is known to interact with and affect the way some other medications work.


Q: What populations were included in the research studies for Betamaks?

Clinical studies supporting the official uses of Betamaks were generally conducted in adult patients. These studies focused on adults diagnosed with the specific conditions being managed, such as schizophrenia and certain vertigo syndromes.


Q: When is the best time of day to take Betamaks?

The medicine is typically prescribed to be taken in divided doses twice daily. The recommended timing, as noted in official posology information, is generally with one dose in the morning and the second dose in the early evening.


Q: What should I do if the side effects are bothering me?

Regulatory guidance indicates that if any side effects persist, worsen, or become troublesome, they should be discussed with a doctor or pharmacist. This is the necessary step to ensure the appropriate management of symptoms.


Q: Are there any known interactions with herbal supplements?

Official patient leaflets contain specific advice for patients to inform their health professional if they are taking any herbal medicines. Herbal products can potentially affect the way Betamaks works in the body, requiring disclosure to ensure treatment safety.


Q: How long does Betamaks stay in your system?

The plasma half-life of the active ingredient, Sulpiride, is the time it takes for half of the drug to be eliminated from the bloodstream. This half-life is typically reported in regulatory documents to be approximately 6 to 8 hours.


Q: Can Betamaks cause skin sensitivity to the sun?

Official safety information confirms that the medicine can cause skin to become more sensitive to sunlight than usual (photosensitivity). Official safety information includes the instruction to protect the skin from bright sunlight until the patient knows how they react.


Q: Can people with liver disease use Betamaks?

Since the drug is predominantly excreted by the kidneys, dose adjustments are generally not required for patients with hepatic (liver) impairment. However, elevations in liver enzymes have been reported with the use of Betamaks, and the potential for elevated liver enzymes means careful monitoring may be warranted.


Q: Is Betamaks a maintenance drug?

Betamaks is not explicitly classified using the specific term 'maintenance drug' in regulatory documents. However, for certain indications, the duration of treatment is described as generally long-term, requiring regular monitoring by a health professional.

Advertisements

How should Betamaks be stored and disposed of?

How to Store and Dispose of Betamaks (Sulpiride)

Official regulatory documents define specific conditions to maintain the stability and safety of Betamaks (Sulpiride).

Storage Conditions

Requirement Official Instruction
Temperature Do not store above 25°C.
Protection Store away from direct sunlight, heat, and moisture.
Child Safety Keep out of the sight and reach of children.
Stability Labeled shelf-life is 3 years when stored under the required conditions.

Disposal Instructions

Disposal of any unused or expired Betamaks must be done in accordance with local regulations. The medicine must not be thrown into water systems, such as sinks or toilets, unless specifically instructed by a regulatory authority. General guidance advises taking unused product to a community pharmacy or approved collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Betamaks found in:

A-Z Index: